News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Kindred Bio (KIN) Announces Second Quarter 2017 Financial Results



8/8/2017 8:02:08 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
SAN FRANCISCO, Aug. 7, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2017 and provided updates on its programs.

"We continue to look forward to our two upcoming approvals and launches. The commercial preparations for the launches are proceeding well and the feedback from the top opinion leaders on both of our products has been very positive," stated Richard Chin, M.D., President and CEO of KindredBio. "We are continuing to make excellent progress across our pipeline, and are pleased to announce the completion of our state-of-the art, full cGMP biologics plant in California. In addition, the recent purchase of the 180,000-square foot manufacturing plant in Kansas will allow us to meet the anticipated market demand for our deep pipeline of biologics."

Read at PR Newswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES